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We have developed a magnetic particle-based assay platform in which functionalised magnetic particles
are transferred sequentially through laminated volumes of reagents and washing buffers. Lamination of
aqueous liquids is achieved via the use of phaseguide technology; microstructures that control the
advancing air–liquid interface of solutions as they enter a microfluidic chamber. This allows manual filling
of the device, eliminating the need for external pumping systems, and preparation of the system requires
only a few minutes. Here, we apply the platform to two on-chip strategies: (i) a one-step streptavidin–biotin
binding assay, and (ii) a two-step C-reactive protein immunoassay. With these, we demonstrate how
condensing multiple reaction and washing processes into a single step significantly reduces procedural
times, with both assay procedures requiring less than 8 seconds.Introduction
Magnetic microparticles have been used extensively in clinical
procedures for a number of years now, and for good reason.1–4
Typically consisting of a core of iron oxide nanoparticles in a
polymer or silica matrix, these microparticles exhibit super-
paramagnetic properties, meaning that they are only magnetic
in the presence of a magnetic field; when the field is removed
they lose their magnetic properties and are able to redisperse
in a solution. Their small size yields high surface-to-volume
ratios, and they are available commercially with a range of
surface functionalities that make them applicable to a num-
ber of applications. Such applications can include isolation
and separation of target analytes (cells, proteins, DNA), DNA
analysis, cell assays, and immunoassays. Conventional mag-
netic particle-based assays, involving the sequential transfer
of reagents and washing buffers to/from sample vials, offer
high capture efficiencies and minimal particle loss. However,they are batch processes, and suffer from having multiple
manual steps that are both laborious and time-consuming.
The incorporation of magnetic particle manipulation into
microfluidic immunoassay procedures5–7 over the last decade
or so has allowed the benefits of the former to be combined
with the typical advantages associated with miniaturisation.
These include a reduction in sample/reagent volumes and
diffusion distances, and a small footprint that makes
portability and point-of-care feasible. Many microfluidic-based
magnetic particle assays are performed using a “trap-and-
release” methodology, in which a plug of functionalised
particles is trapped within a microchannel and has solutions of
reagents and washing solutions washed over it consecutively.8–11
In recent years there has been a shift towards performing
continuous flow assays in order to reduce these multi-step
procedures into a single step, decreasing processing times
and introducing a degree of automation. Such methods are
derived from continuous flow separation techniques in which
magnetic particles in a sample stream are pulled into an
adjacent buffer stream to extract a target analyte that has
become bound to the particles.12–16 However, by generating
multilaminar flow streams in a microfluidic chamber, consisting
of alternating streams of reagents and washing solutions,
particles can be deflected consecutively through each stream,
thus performing sequential reactions/binding events.17–24
This concept can also be flipped, in that rather than
deflecting magnetic particles through continuously flowing
streams of solutions via a fixed magnet, they are instead
pulled by a moving magnet through static solutions. These
principles can be observed in some droplet-based systems, in
which aqueous droplets containing samples, reagents, andoyal Society of Chemistry 2014
Fig. 1 Principles of magnetic particle-based assays employing lamination
of reagents and buffers for (a) a one-step streptavidin–biotin assay, and
(b) a two-step CRP sandwich immunoassay. Functionalised magnetic
particles are pulled through lanes of reagents and washing buffers
formed via the use of phaseguides (shown as grey lines in the
microfluidic chamber).
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View Article Onlinebuffers are immersed in an immiscible phase such as oil25–29
or air,30–33 and a magnet used to move particles between the
droplets. A recent development utilising a similar principle
involves the generation of aqueous regions of samples,
reagents and washing buffers, separated by an immiscible
phase that forms barriers between the aqueous solutions.
This prevents samples and reagents from mixing together,
yet allows magnetic particles to cross the immiscible phase
when pulled by an external magnet, thus transferring the
particles between the reaction and labelling regions.
A prime example of the transfer of particles across immis-
cible barriers is “immiscible filtration assisted by surface
tension” (IFAST), in which microfluidic chambers, linked by
small “gate” regions, are alternately filled with aqueous and
oil-based solutions.34 IFAST, and variants such as VerIFAST35,36
and SNARE (selective nucleic acid removal via exclusion),37
has mostly seen applications in DNA purification34,37 and cell
isolation,35,36,38 but has also been demonstrated for immuno-
assays.39 Several other devices have been developed that
utilise a variety of immiscible phases, including liquid wax,40
paraffin,41 and air.42–45
However, while the movement of magnetic particles across
static regions of assay solutions has developed as a fast and
robust technique, it is not particularly necessary to use
immiscible solutions. Becker et al.46,47 have shown a “stationary
fluidics” device in which magnetic particles are pulled through
a chain of reaction compartments to perform DNA washing
and amplification, using only aqueous solutions. The geometry
of the compartments was designed to minimise crossover of
reagents between chambers. A variant of this system from
Gottheil et al.48 was also recently demonstrated in which
phaseguides were applied to the bubble-free filling of the
device, and the chambers were connected by a passive valve
that formed a small bridge between the compartments.
Here, we present a new method of filling a microfluidic
device with stationary fluids for magnetic particle-based assays,
which harnesses phaseguide technology for the generation of
adjacent regions of aqueous liquids. This essentially allows the
device to “mimic” platforms that use immiscible solutions,
while actually consisting entirely of miscible solutions.
Phaseguides are lines of microstructures that are incorpo-
rated onto the floor of a microfluidic channel, and are around
one-quarter the height of the microchannel.49,50 Starting with
a dry, empty device, the phaseguides direct the advancing air–
liquid interface as a solution is introduced into the channel,
with the meniscus being pinned on the phaseguide. Crucially,
the advancing liquid will be unable to cross the phaseguide
until the section of chip bordered by the phaseguide is full, at
which point the pressure build-up across the meniscus is
such that the phaseguide is breached and liquid will advance
into the next section of the chip. The liquid overflows the
phaseguide at the point of least resistance, hence by incorpo-
rating this fact into the design of the phaseguides the route
by which the liquid takes during filling of the chip can be pre-
cisely controlled. This powerful technique is therefore capable
of allowing complex channel geometries, in particular thoseThis journal is © The Royal Society of Chemistry 2014with sharp corners, to be filled without having air bubbles
become trapped within the device, since all of the air is forced
out by the advancing liquid. Microfluidic platforms that have
taken advantage of phaseguide technology have included
those for the separation and purification of analytes,51 the
recovery of dielectrophoretically separated cells and parti-
cles,49 the extraction of low molecular weight RNA,52 the
enrichment of bacteria by free-flow electrophoresis,53,54
isothermal amplification of DNA,55 lysis of bacteria and puri-
fication of the released RNA,56 and stratified 3D cell culture.57
We report the application of phaseguide technology for
the lamination of “lanes” of aqueous solution through which
functionalised magnetic particles are manoeuvred (Fig. 1).
Immunoassays are performed by generating alternating lanes
of reagent and washing buffer solutions, and as the particles
move sequentially through each lane the target analyte
becomes bound to the particles and is subsequently labelled.
Two proof-of-principle assay procedures are described here to
highlight the platform's potential suitability for clinical diag-
nostics: (i) a one-step streptavidin–biotin binding assay
(Fig. 1a), and (ii) a two-step C-reactive protein sandwich
immunoassay (Fig. 1b). This phaseguide-assisted platform
has the benefits of allowing the filling of the device without
the need for external pumping mechanisms (e.g. syringe pumps),
while the assay itself is controlled by manual movement ofLab Chip, 2014, 14, 2334–2343 | 2335
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View Article Onlinethe magnet across the top of the chip. These aspects yield a
simple yet rapid process in terms of both chip preparation
and of performing the magnetic particle-based assay.Experimental
Chip design and fabrication
The design of the microfluidic device is shown in Fig. 2a.
The layout featured a large rectangular chamber (4 mm long ×
10 mm wide) that was split into five “lanes”, each having a
width of 2 mm and a length of 4 mm. Each lane was fed by a
single inlet channel (200 μm width), and air vent channels
(200 μm width) were situated at the top of the chamber,
between the adjacent lanes, to allow air to be expelled during
the filling of the system. Each lane featured phaseguides that
were designed to direct the advancing air–liquid in such a
manner as to fill only one lane from each inlet hole, whilst
expelling all of the air from that lane. Each lane was sepa-
rated by two parallel lines of phaseguides that “kinked” near
the lower wall of the chamber (shown in Fig. 2a with angles
α1 and α2), with these kinks determining where the air–liquid
interface overflowed into the adjacent lane.2336 | Lab Chip, 2014, 14, 2334–2343
Fig. 2 (a) Design of the microfluidic device, illustrating the phaseguide
pattern that generates five individual lanes. (b) Photograph of the
microfluidic device and the 20 × 10 × 5 mm3 NdFeB magnet used to
manipulate the magnetic particles. (c) Simulation of the magnetic field
produced by the magnet in relation to the phaseguide chip (side view).The device was fabricated on a glass substrate using a dry
film resist, Ordyl SY-330 (Elga Europe, Italy), as the structural
material.58,59 The Ordyl was laminated onto a soda lime glass
wafer (Berlin Glass, Germany) and exposed with 240 mJ cm−2
using a mask aligner to pattern the phaseguide layout onto
the film resist. An additional three layers of Ordyl were lami-
nated and exposed in the same manner to build up the
chamber/channel geometry, before being baked at 85 °C for
1 min. The resist was developed in three baths of BMR devel-
oper (Elga Europe) with increasing purity, followed by rinsing
with isopropanol and water, and finally being spun dry. The
process yielded phaseguides that were approximately 30 μm
in height and 50 μm in width, and a channel structure that
was 120 μm in height.
Access holes were ultrasonically drilled into a second soda
lime glass wafer. After cleaning the drilled wafer, it was
bonded to the patterned wafer using a heated press at a
temperature of 95 °C and a pressure of approximately 60 N cm−2
for 30 min.
Preparation of solutions
All solutions were prepared using high purity water (18.2 MΩ cm
at 25 °C) that had been double-filtered (0.05 μm, ELGA Option
4 feeding into an ELGA UHG PS system, ELGA Process Water,
Marlow, UK). Phosphate buffered saline solution (PBS,
pH 7.45) was prepared by dissolving a 5 g tablet (Invitrogen,
Life Technologies, Paisley, UK) in 500 mL water, with 0.05%
w/v Tween20 (Sigma-Aldrich, Dorset, UK) added to prevent
particles sticking to the microchannel surfaces and to each
other. A solution of fluorescently labelled biotin was prepared
by dissolving biotin-4-fluorescein (λex = 494 nm, λem = 521 nm,
Invitrogen) in PBS solution.
Lyophilised recombinant C-reactive protein (CRP, R&D
Systems, Abington, UK) was reconstituted in 20 mM tris buffer
(pH 8, Sigma-Aldrich), with 0.1% bovine serum albumin (BSA,
Sigma-Aldrich) added, to a stock concentration of 200 μg mL−1
as per the manufacturer's instructions. Biotinylated primary
CRP antibody (1° Ab, monoclonal mouse anti-human C-reactive
protein, R&D Systems) was purchased as a lyophilised powder
and reconstituted in PBS to a stock concentration of
50 μg mL−1, as per the manufacturer's instructions. Fluores-
cently labelled secondary CRP antibody (2° Ab-FITC, polyclonal
goat anti-human C-reactive protein conjugated to fluorescein
isothiocyanate, λex = 495 nm, λem = 521 nm) was purchased as
an aqueous solution at a concentration of 10 mg mL−1
(Abcam plc., Cambridge, UK).
Preparation of particle suspensions
Stock magnetic particle suspensions were prepared by dis-
persing streptavidin-functionalised 2.8 μm diameter particles
(Dynabeads M-270 Streptavidin, Invitrogen) in PBS solution.
10 μL of the particle suspension provided (6.5 × 108 particles mL−1)
was added to a 1.5 mL Eppendorf tube (VWR, Leicester, UK),
before being washed three times with PBS. 1000 μL of PBS
was added to the tube, after which the tube was vortexed and
the magnetic particles pulled to the side of the tube via anThis journal is © The Royal Society of Chemistry 2014
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View Article Onlineexternal magnet. This allowed the supernatant to be removed
via a pipette while the particles remained in the tube, enabling
a further 1000 μL of PBS to be added in order to repeat the
washing process. From here, the particles would be treated in
one of two manners depending on whether they were to be
used for the one-step streptavidin–biotin binding assay or the
two-step CRP sandwich immunoassay.
In order to perform the one-step biotin–streptavidin binding
assay, the particles were resuspended in 50 μL of PBS to a con-
centration of 1.3 × 108 particles mL−1, and were stored at 4 °C
until ready for use.
The magnetic particles required further treatment when
performing the two-step CRP assay. Following the final PBS
washing step, the supernatant was removed and 200 μL of 1°
Ab solution (10 μg mL−1) was added to the Eppendorf tube,
then allowed to incubate for 15 min with agitation. This
allowed the biotinylated primary antibody to bind to the
streptavidin groups on the particles. The particles were
washed three times with PBS and finally suspended in 50 μL
of PBS to a concentration of 1.3 × 108 particles mL−1, and
stored at 4 °C until ready for use.
Chip setup and operation
The microfluidic device was filled with liquids by consecu-
tively introducing aqueous solutions (1.5 μL) into the inlet
holes (1–5) via a pipette (Eppendorf). Each pipetting step
filled up one lane of the assay. The chip was then placed onto
the sample stage of an inverted fluorescence microscope
(TE-2000, Nikon, Surrey, UK) for visualisation of the magnetic
particles. Images were captured via a CCD camera
(Retiga-EXL, QImaging, Media Cybernetics, Buckinghamshire,
UK) and Image-Pro Plus 6.2 software (Media Cybernetics, UK).
Fluorescence measurements of the particles were performed
using ImageJ software (http://rsb.info.nih.gov/ij/).
A large, rectangular neodymium–iron–boron (NdFeB) mag-
net (20 × 10 × 5 mm3, Magnet Sales, Swindon, UK) was placed
on top of the chip, above the chamber in such a position that
the left edge of the magnet was located over the interface
between lanes 1 and 2 in the chip (Fig. 2b). Fig. 2c shows a
simulation of the magnetic field generated across the
microfluidic chamber (from a side view) at this starting
position, which was generated using FEMM 4.2 software
(http://femm.foster-miller.net). It can clearly be seen that the
bottom-left corner of the magnet provides a very large mag-
netic field and gradient, thus the particles in the chip will be
attracted towards this edge and follow it as the magnet is
moved to the right.
During experiments, magnetic particles were introduced
into lane 1 of the microfluidic device, while lanes 2–4
contained different combinations of reagents and washing
buffer solutions (depending on the experiment) and lane 5
consisted of PBS washing buffer. To perform an assay, the
magnet was moved by hand from left-to-right across the chip.
This caused the magnet to move from its starting location to
a position at which the left edge of the magnet was situated
over the right-hand side of lane 5. As the magnet was movedThis journal is © The Royal Society of Chemistry 2014across the chamber, the magnetic particles followed the
magnet, crossing each lane from lane 1 to lane 5 where they
came to a stop in the PBS wash buffer. Images of the
particles were then captured for fluorescence analysis, and
compared to images taken before the magnet was moved.
This technique was used to perform two types of assay: (i) a
proof-of-principle one-step streptavidin–biotin binding assay,
and (ii) a two-step CRP sandwich immunoassay.
Streptavidin–biotin binding assay
In order to first test the system for performing magnetic
particle-based assays, a one-step streptavidin–biotin binding
assay was attempted. Streptavidin functionalised magnetic
particles (1.3 × 108 particles mL−1, yielding 2 × 105 particles
in the chamber) were introduced into lane 1 of the microfluidic
device, while fluorescently labelled biotin was introduced into
lane 3, and PBS washing buffer into lanes 2, 4 and 5 (Fig. 1a).
Biotin concentrations of 1 to 100 μg mL−1 were tested.
C-reactive protein immunoassay
A sandwich immunoassay was set up by introducing 1.5 μL
of primary antibody (1° Ab) coated magnetic particles
(1.3 × 108 particles mL−1, yielding 2 × 105 particles in the
chamber) into lane 1 of the microfluidic device, CRP into
lane 2, fluorescently labelled secondary antibody (2° Ab-FITC,
100 μg mL−1) into lane 4, and PBS washing buffer into lanes
3 and 5 (Fig. 1b). CRP concentrations of 0.1 to 1 μg mL−1
were investigated.
Results
Liquid lamination
Fig. 3a–c shows the chip filling process in ordered lanes
using orange and blue dyes as an example. Firstly, liquid is
introduced into lane 1 to the point where the lane is full but
has not overflowed past the phaseguide separating it from
lane 2 (Fig. 3a). Liquid is then injected into lane 2 until the
lane is full but there has been no overflow across the separa-
tion phaseguides. Finally, a small burst of extra pressure
from the pipette forces the liquid in lane 2 to cross the
phaseguides separating it from lane 1 (but not lane 3) at the
kinked sections of the phaseguides (Fig. 3b). This bridges the
liquids in lanes 1 and 2 and forces the air out of the vent at
the top of the chamber, thereby allowing lamination of the
two liquids in a static form. This process of adding liquids to
adjacent channels is repeated in turn for lanes 3 to 5 until
the entire microfluidic chamber has been filled that consists
of five lanes of laminated solutions (Fig. 3c). By changing the
solutions in each lane it was possible to prepare the chip in
such a manner as to perform one-step and two-step assays.
Streptavidin–biotin binding assay
Streptavidin functionalised magnetic particles were intro-
duced into lane 1 of the microfluidic chamber, with fluores-
cently labelled biotin in lane 3 and PBS in lanes 2, 4 and 5
(Fig. 4a). The filling of each lane with 1.5 μL solutionLab Chip, 2014, 14, 2334–2343 | 2337
Fig. 3 (a) Filling of lanes 1 and 2 with ink, with the blue ink in lane two
crossing into the space between the lanes at position α2. (b) Applying a
little extra pressure bridges the gap between the lanes, forcing the air
out of the vent and laminating the two liquids. (c) Filled device
featuring five laminated lanes of different aqueous solutions.
Fig. 4 (a) Photograph of the phaseguide chip containing a central
lane of fluorescent biotin. (b) Photographs of particles before and after
passing through the biotin lane. The overview of the entire chip is a
false-coloured photograph to highlight where the lanes would be. (c)
Fluorescence intensities of the particles after passing through different
concentrations of biotin.
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View Article Onlinerequired ~30 s by pipette, and so the total filling of the
chamber required ~150 s (2.5 min). Placing the magnet in its
starting location required only a few seconds as it was not
required that the position be particularly accurate, as long as
the left edge of the magnet was somewhere over lane 1.
When the magnet was moved from left-to-right across the top
of the chip the magnetic particles followed its movement,
passing through the lane of biotin and into the lanes of PBS
washing buffer. The buffer solution provided a “washing
step” as the particles moved through the solution, removing
unbound material from the surfaces of the particles. Impor-
tantly, the time taken to move the magnet over the chamber,
and thus the time needed to move the particles through the
lanes, was only 8 s, thereby making the assay incredibly fast.
Fig. 4b shows photographs of the magnetic particles
before and after passing through the lane of fluorescently
labelled biotin. The images clearly demonstrate the increase
in fluorescence intensity once they have migrated through
the reagent, indicating successful binding of the biotin to the
streptavidin functionalised particles. The assay was repeated
with biotin concentrations of 1, 10 and 100 μg mL−1, and the
fluorescence intensities of the particles were measured when
the particles were in lane 5 (having traversed the biotin lane).2338 | Lab Chip, 2014, 14, 2334–2343The fluorescence intensities of the particles in lane 1 before
beginning the assay were also measured, since the polystyrene
matrix of the particles exhibits auto-fluorescence. Twenty par-
ticles were measured in each instance, and the results are
shown in Fig. 4c. Here, it was found that increasing the biotin
concentration yielded an increase in fluorescence intensity of
the particles, and while optimisation of the platform is still
required the results nonetheless demonstrate its potential for
quantitative analysis.This journal is © The Royal Society of Chemistry 2014
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View Article OnlineAn important factor to consider when dealing with lami-
nated aqueous solutions is the extent of diffusion between
the reagent and the buffer solutions. Over time, the two will
slowly diffuse into each other, affecting the concentration of
biotin through which the particles pass and therefore
limiting the ability to perform quantitative assays. Observing
the extent of diffusion of biotin over time showed that 5 min
after filling the chip, some diffusion had occurred but the
biotin was largely contained as a well-defined column in the
chamber (Fig. 5a). However, 10 min after filling the chip the
effect of diffusion was far more noticeable, with the biotin
dispersing across a large region of the chip and having
different concentrations of biotin in different areas (Fig. 5b).
Bearing in mind, however, that once the chip was filled it
required several seconds to position the magnet and then 8 s
to perform the assay, the amount of diffusion would largely
be negligible.
Combined with the fact that the chip requires only a few
minutes to set up and several seconds to perform the assay,
this would make it a powerful tool for performing rapid,
quantitative assays without the need for a pumping mecha-
nism. In order to investigate the potential of the platform for
more clinically relevant immunoassays, the inflammatory
biomarker, C-reactive protein, was chosen for initial tests.C-reactive protein immunoassay
C-reactive protein (CRP) is an acute phase protein found in
blood whose concentration increases in response to inflam-
mation or infection.60,61 As such, it is routinely measured in
clinical diagnostics. Normal levels of CRP in serum are
typically 1–10 μg mL−1, while levels of 10–40 μg mL−1 indicate
mild inflammation or viral infection, and levels of 40–200 μg mL−1
suggest active inflammation or bacterial infection. Furthermore,This journal is © The Royal Society of Chemistry 2014
Fig. 5 Photographs showing diffusion of a lane of fluorescent biotin
after (a) 5 min, and (b) 10 min after complete filling of the chip with
solutions.chronic, minor elevations in CRP may also be indicative of
cardiovascular disease.62,63
To perform a sandwich CRP assay, lane 1 of the micro-
fluidic device was filled with a suspension of primary anti-
body (1° Ab) functionalised magnetic particles, lane 2 with a
solution of CRP, lane 4 with fluorescently labelled secondary
antibody (2° Ab-FITC), and lanes 3 and 5 with PBS washing
buffer. When the magnet was moved across the top of the
chip, the particles were pulled through the lane containing
CRP, whereupon the protein became bound to the antibodies
on the particles, before entering the lane of wash solution in
order to remove unbound material from the particle surfaces.
The particles then passed through the lane of 2° Ab-FITC,
which became bound to the CRP now present on the parti-
cles, thereby fluorescently labelling them. Finally, the parti-
cles passed into the final lane of wash solution and to the
edge of the chamber, allowing unbound material to be
washed from the particles and for images to be captured for
fluorescence analysis. As in the one-step streptavidin–biotin
reaction, the entire sandwich immunoassay required only 8 s:
the time taken for the magnet to be moved across the chip.
Fig. 6a shows photographs of the magnetic particles
before and after passing through the chamber, and clearly
demonstrates the increase in fluorescence intensity of the
particles after they had passed through each of the reagent
and washing lanes. As before, the particles exhibited a slight
fluorescence signal due to auto-fluorescence of the polysty-
rene matrix. The experiment was repeated with varying con-
centrations of CRP: 0.1, 1 and 10 μg mL−1. Results showed
that the fluorescence intensity of the particles increased with
increasing concentration (Fig. 6b, twenty particles were
analysed in each case). However, it can be observed that
the signal is approaching saturation as the concentration of
CRP reaches 10 μg mL−1. This is likely due to the CRP
approaching, or even reaching, the binding capacity of the
magnetic particles at these higher concentrations, which
would saturate the fluorescence signal and prevent further
increases even if higher CRP concentrations were used.
Despite the fluorescence approaching saturation between 1
and 10 μg mL−1, a one-tailed Welch's T-test showed a statisti-
cally significant difference at a confidence level of 95%,
although at higher confidence levels (≥97.5%) the difference
between these two signals was no longer statistically signifi-
cant. The differences between the signals at the other CRP
concentrations (i.e. between 0 and 1 μg mL−1) remained sig-
nificant even at 99.5% confidence levels. Thus, the assay
shows promise for the quantitative detection of CRP,
although optimisation will be required to ensure statistical
significance between all CRP concentrations tested, and to
investigate the linear range and limit of detection.
Negative control tests were also performed in which
streptavidin functionalised particles were pulled through
each of the lanes, with the results (not shown) illustrating
that no increase in fluorescence could be obtained without
using 1° Ab functionalised particles. When only streptavidin
functional groups were present on the particles surfaces, theLab Chip, 2014, 14, 2334–2343 | 2339
Fig. 6 (a) Photographs of magnetic particles before and after passing
through the reagent and washing lanes during the two-step CRP
sandwich immunoassay. An increase in fluorescence intensity of the
particles represents the binding and labelling of CRP. The overview
photograph of the chip is false-coloured to allow visualisation of the
position of the lanes. (b) Fluorescence intensities of the magnetic
particles at different CRP concentrations.
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View Article OnlineCRP would not be able to bind to the particles, and so there
would be nothing for the 2° Ab-FITC to bind to as the particles
passed through lane 4. This demonstrates that non-specific
binding is not a problem, as any biomolecules that have
absorbed onto the particles will be washed off as they are
pulled through the washing lanes. Furthermore, no fluores-
cence increase was observed of 1° Ab particles that had been
pulled through the CRP lane until they then passed through
the 2° Ab-FITC lane. Off-chip tests were also performed in
Eppendorf tubes to ensure that the on-chip processes followed
the same progression as the off-chip procedures.
This proof-of-principle immunoassay demonstrates the
potential of the platform for quantitative analysis of clinically
relevant biomarkers. The system, which utilises liquid
lamination via the incorporation of phaseguide structures
into the microfluidic device, offers a simple yet controllable
means of filling the device with miscible solutions, offering
fast chip setup times (a few minutes) and rapid immuno-
assays (8 s). The platform shows great promise for point-of-care2340 | Lab Chip, 2014, 14, 2334–2343analysis, particularly as it does not require the use of a
pumping mechanism, instead needing only manual pipetting
of the reagents, making it promising as a portable system.
However, before this can be realised there are several factors
that could be optimised or incorporated into the platform,
which will be discussed in the next section.
Discussion and outlook
This paper reports for the first time a stratification of
miscible liquids in orderly lanes. Phaseguides have been used
for stratification in earlier publications; however this
required gelation steps to maintain the stratified profile.
Stratification of miscible liquids is not possible in micro-
fluidic chambers without adding an additional engineering
complexity. Without phaseguides, liquid would spread radi-
ally and multiple liquids spread as one once they are brought
in contact. The trick in the work presented here is that fluids
are (1) manipulated in a rectangular shape while (2) keeping
them separated until the filling process is near completion,
followed by (3) filling of the small air gap that exists between
the two liquids by (4) forcing phaseguide overflow at a posi-
tion distal from a venting channel.
The phaseguide-assisted liquid lamination platform has
been shown here to be capable of performing magnetic
particle-based assays in both one-step (streptavidin–biotin)
and two-step (CRP) formats. Given that these were proof-of-
principle assays designed to showcase the core principles of
the system, the next steps in terms of assays would be investi-
gations into other clinically relevant biomarkers (e.g. for
cardiac disease, sexually transmitted infections, and various
diseases), as well as the transition to looking at real clinical
samples rather than standard solutions. In addition to immu-
noassays, it should be relatively easy to extend the technique
to solid-phase extraction and nucleic acid assays, enabling
DNA and RNA analysis from a sample matrix.
Clearly, as different biomarkers are investigated they may
require slight changes to the way in which the procedure is
carried out. For example, some assays may require longer
incubation times due to slow reaction kinetics. This could be
accounted for by increasing the width of the reagent lanes to
increase the length of time the particles spend in each lane,
moving the magnet more slowly across the chip, or simply
holding the magnet in place over a particular reagent lane for
a period of time to ensure the reaction occurs.
The current setup employs a conventional inverted
fluorescence microscope; a somewhat limiting factor when
attempting to transfer a technology to the portability and
point-of-care stage. However, given the recent advances in
miniaturised optical detection systems,64,65 we envisage the
incorporation of such technology into a more complete setup
at a later stage of development. Regarding the potential for
mass production of the device itself, current chip fabrication
is achieved by lamination methods that are already common-
place in the printed circuit board and biosensor industries.
Still, it would also be possible to fabricate chips by injectionThis journal is © The Royal Society of Chemistry 2014
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View Article Onlinemoulding or hot embossing via the use of a precision milled
master, and this has very recently been demonstrated for
phaseguide chip production by Gottheil et al.48 Nonetheless,
the design principles would remain the same for mass
produced chips as for the prototype shown here.
Filling the lanes of the microfluidic chip with reagents
and buffers is straightforward due to the incorporation of the
phaseguide structures. The manual pipetting removes the
need for an external syringe pump, yielding a static fluidic
system in the chip, and requires only around 30 s of filling
per lane. However, manual pipetting can sometimes succumb
to human error during the filling of the system, particularly
when “bridging” the gap between two lanes as the filling of
the second lane nears completion. An accidental burst of
pressure can force the liquid across the gap and into the
adjacent lane, distorting the “shape” of the liquids within the
lanes. When this occurs it seldom has a significant effect on
the rest of the procedure, but in extreme circumstances it
could affect the width of the reagent lanes and therefore the
volume of reagent that the particles interact with. To prevent
this from happening, steps could be taken to ensure a more
reproducible filling procedure. In particular, blister packs66
containing the solutions could be placed over the inlet holes
of the device, and actuated using a mechanical system that
could be operated by hand (e.g. a “rolling pin” type assembly
that rolls over the surface the device, bursting each blister
pack in turn, or a series of pins that can be pressed onto the
blister packs). The blister packs could be designed to contain
just the right amount of volume to fill a lane, and a
controlled mechanism for bursting them would ensure a
reproducible filling.
When storing reagents in aqueous form is not viable (due
to short lifetimes of the reagents) it may be possible to
lyophilise the reagents67 as spots in the inlet channels of the
microfluidic device, such that when a blister of buffer solu-
tion is burst it reconstitutes the reagent and fills the lane.
Returning to the issue of reagent diffusion discussed earlier,
the effects of diffusion could be greatly limited by the
proposed mechanical setup, since always having the same
chip preparation time followed immediately by the assay will
ensure that the effect of diffusion is always the same, rather
than running the risk of having diffusion affect one experi-
ment more than another when performed manually.
As can be seen in Fig. 2b, multiple microfluidic devices
can be produced on a single wafer, which could be exploited
to perform calibration assays alongside an assay of a sample,
thereby generating all the data necessary for a quantitative
analysis on one device. The incorporation of phaseguide-
based mixing structures55 into the device could also enable
automated dilution of reagents for a calibration, with the
phaseguides allowing differing volumes of buffer solution to
mix with a reagent solution in order to generate a dilution
series without needing to pre-dilute the reagents.
Currently, the magnet is moved by hand in order to pull
the particles across the chamber. This has the major benefits
of keeping the platform simple, easy to use and power-free.This journal is © The Royal Society of Chemistry 2014However, it can also introduce some human error since
moving the magnet at different rates would affect the expo-
sure time of the particles to the sample and reagents. Despite
this, repeats of experiments have shown that there is little
difference in results, and so long as the movement of the
magnet is slow enough to allow the binding events to occur
then the movement speed should not cause any great
discrepancies. Clearly, moving the magnet too fast would also
result in the particles being unable to follow, and so there
will be a compromise between the desire for a fast procedure
and the time required for the binding events to occur. A total
movement time of 8 s was sufficient for the assays performed
here, but other reactions, assays and extractions may require
longer residence times in the sample or reagent lanes, as
explained earlier. In principle, a lead screw and motor system
could be constructed for automated, controllable and repro-
ducible movement of the magnet, but this would add a
degree of complexity that we are trying to avoid in this plat-
form in terms of keeping the device simple and easy to use.
The various tools proposed above represent potential
directions in which to take the development of the magnetic
particle-based assay platform for future devices. However, the
core elements of the system have been demonstrated here: (i)
the formation of static, adjacent lanes of reagent and
washing solutions via phaseguide-assisted filling of the
device, thereby eliminating the need for external syringe
pumps, (ii) rapid magnetic particle-based assays, in both one-
step and two-step format, in which the chip setup takes only
a few minutes and the assay itself requires only 8 seconds.
Future work would involve optimisation of the device and its
operation, which would allow studies into linear ranges and
limits of detection for different biomarkers.
Conclusions
We have demonstrated the use of phaseguide structures to
achieve the sequential lamination of five aqueous liquids in a
microfluidic chamber. Filling of the chamber is achieved via
manual pipetting, eliminating the need for external pumping
systems, and requires only a few minutes. Magnetic particle-
based assays have been performed in the system by drawing
functionalised magnetic particles consecutively through each
“lane” of reagent and washing buffer via an external magnet,
requiring only 8 seconds to perform one-step and two-step
reactions. Extension of the protocol to solid-phase extraction
and nucleic acid assays should be straightforward, making
the platform far more versatile in the future, and we can
envisage a number of technological developments for optimi-
sation of the system and procedure.
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